Immuneel Therapeutics partners Impact Guru & CarePal Money to improve financial access to CAR T-Cell therapy in India

New Delhi: Addressing one of the most persistent barriers to advanced cancer care in India, Immuneel Therapeutics recently announced strategic partnerships with Impact Guru, a leading healthcare crowdfunding platform, and CarePal Money, a healthcare-focused lending marketplace.

The collaborations aim to significantly improve financial access to CAR T-cell therapy for patients across diverse socio-economic backgrounds.

CAR T-cell therapy is among the most advanced and personalised treatments available today for certain blood cancers, offering renewed hope to patients with relapsed or refractory disease. However, access to these therapies has been constrained by high upfront costs and limited financing options. Through this integrated access model, Immuneel seeks to address a core challenge facing advanced therapies in emerging markets: affordability and financial preparedness.

Under the partnership, Impact Guru will enable patients and families to raise funds through its digital crowdfunding platform, mobilising community support via donation campaigns and awareness drives backed by a donor network of over 50 lakh contributors. CarePal Money will facilitate structured credit solutions by connecting eligible patients with its network of NBFC partners, offering tailored loan and financing options for medical treatment.

Immuneel Therapeutics will continue to deliver globally benchmarked CAR T-cell therapies in India, while working closely with both partners to ensure timely financial support alongside clinical care.

Commenting on the collaboration, Amit Mookim, Board Director and Chief Executive Officer, Immuneel Therapeutics, said, “Scientific innovation alone does not transform cancer care. Real impact comes when breakthrough therapies reach patients who need them most, regardless of financial circumstance. Through our partnerships with Impact Guru and CarePal Money, we are building a more holistic access ecosystem that combines clinical excellence with financial enablement, aligned with India’s ambitions in advanced therapeutics and universal health coverage.”

Piyush Jain, Co-Founder and CEO, CarePal Group and Impact Guru, added, “Healthcare innovation needs inclusive financing models. This partnership creates a dual pathway: patients can mobilise community support through Impact Guru’s crowdfunding platform while also accessing structured credit through CarePal Money’s NBFC partners. Together, this offers both flexibility and financial security at a critical time.”

Sahil Lakshmanan, Chief Business Officer, CarePal Money, said, “As medical innovation advances, healthcare financing must evolve alongside it. By institutionalising credit access for advanced therapies through our NBFC partnerships, we aim to reduce financial shock for families and support continuity of care.”

The collaboration represents a scalable access framework for emerging markets, where medical advances must be matched with sustainable financing solutions. By integrating advanced cell and gene therapies with digital crowdfunding and structured healthcare lending, the partners aim to complement public health systems, insurance coverage, and future reimbursement pathways for CAR T-cell therapy. As these treatments become more integral to modern oncology, the partnership signals a shift towards ecosystem-led healthcare delivery, where innovation, financing, and policy objectives converge to improve patient outcomes at scale.